参考文献:
[1]YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3): 221-241.
[2]XIAO XH, TANG JY, MAO YM, et al. Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury[J]. Acta Pharm Sin B, 2019, 9(3): 648-658.
[3]ZHOU Y, YANG L, LIAO Z, et al. Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21,789 patients[J]. Eur J Gastroenterol Hepatol, 2013, 25(7): 825-829.
[4]SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241.e11.
[5]CHEN M, SUZUKI A, BORLAK J, et al. Drug-induced liver injury: Interactions between drug properties and host factors[J]. J Hepatol, 2015, 63(2): 503-514.
[6]HOOFNAGLE JH, BJRNSSON ES. Drug-induced liver injury-Type and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273.
[7]STINE JG, CHALASANI N. Chronic liver injury induced by drugs: A systematic review[J]. Liver Int, 2015, 35(11): 2343-2353.
[8]European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury[J]. J Hepatol,2019, 70(6): 1222-1261.
[9]KWO PY, COHEN SM, LIM JK. ACG clinical guideline: Evaluation of abnormal liver chemistries[J]. Am J Gastroenterol,2017, 112(1): 18-35.
[10]U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation[EB/OL]. (2009). https: //www.fda.gov/downloads/Guidances/UCM174090.pdf.
[11]Chinese Medical Association of Chinese Society for Tuberculosis. Guidelines for the diagnosis and treatment of antituberculotic drug-induced liver injury[J]. Chin J Tuberc Respir Dis, 2019, 42(5): 343-356. (in Chinese)
中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(5): 343-356.
[12]CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology,2015, 148(7): 1340-1352.e7.
[13]FONTANA RJ, HAYASHI PH, GU J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset[J]. Gastroenterology, 2014, 147(1): 96-108.e4.
[14]JEONG R, LEE YS, SOHN C, et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury[J]. Scand J Gastroenterol, 2015, 50(4): 439-446.
[15]ROBLES-DIAZ M, LUCENA MI, KAPLOWITZ N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J]. Gastroenterology, 2014, 147(1): 109-118.e5.
[16]MEDINA-CALIZ I, ROBLES-DIAZ M, GARCIA-MUOZ B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J]. J Hepatol, 2016, 65(3): 532-542.
[17]ZHU Y, NIU M, CHEN J, et al. Hepatobiliary and pancreatic: Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients[J]. J Gastroenterol Hepatol, 2016, 31(8): 1476-1482.
[18]JING J, WANG R, ZHAO X, et al. Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb- Polygonum multiflorum thunb. induced liver injury: A case-control study from a specialised liver disease center in China[J]. BMJ Open, 2019. [Epub ahead of print]
[19]LO RS, KRISHNAMOORTHY R, FREEMAN JG, et al. Cholestasis and biliary dilatation associated with chronic ketamine abuse: A case series[J]. Singapore Med J, 2011, 52(3): e52-e55.
[20]SCHWAB GP, WETSCHER GJ, VOGL W, et al. Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis[J]. Langenbecks Arch Chir, 1996, 381(4): 225-227.
[21]HORSLEY-SILVA JL, DOW EN, MENIAS CO, et al. Docetaxel induced sclerosing cholangitis[J]. Dig Dis Sci, 2015, 60(12): 3814-3816.
[22]LIN G, WANG JY, LI N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J]. J Hepatol, 2011, 54(4): 666-673.
[23]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of quinazoline alkaloids - related sinusoidal obstruction syndrome ( 2017,Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. (in Chinese)
中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637.
[24]STINE JG, NORTHUP PG. Autoimmune-like drug-induced liver injury: A review and update for the clinician[J]. Expert Opin Drug Metab Toxicol, 2016, 12(11): 1291-1301.
[25]KLEINER DE, CHALASANI NP, LEE WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations[J]. Hepatology,2014, 59(2): 661-670.
[26]KLEINER DE. Drug-induced Liver Injury: The hepatic pathologist’s approach[J]. Gastroenterol Clin North Am, 2017, 46(2): 273-296.
[27]KULLAK-UBLICK GA, ANDRADE RJ, MERZ M, et al. Drug-induced liver injury: Recent advances in diagnosis and risk assessment[J]. Gut, 2017, 66(6): 1154-1164.
[28]CLARKE JI, DEAR JW, ANTOINE DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety-false dawn or new horizon?[J]. Expert Opin Drug Saf, 2016, 15(5): 625-634.
[29]LUNDBCK P, LEA JD, SOWINSKA A, et al. A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice[J]. Hepatology, 2016, 64(5): 1699-1710.
[30]DEAR JW, CLARKE JI, FRANCIS B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: Results from two prospective cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3(2): 104-113.
[31]CHURCH R, KULLAK-UBLICK GA, AUBRECHT J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort[J]. Hepatology, 2019, 69(2): 760-773.
[32]ANTOINE DJ, JENKINS RE, DEAR JW, et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity[J]. J Hepatol,2012, 56(5): 1070-1079.
[33]HUEBENER P, PRADERE JP, HERNANDEZ C, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis[J]. J Clin Invest, 2015, 125(2): 539-550.
[34]ANDERSSON U, LINDBERG J, WANG S, et al. A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran[J]. Biomarkers, 2009, 14(8): 572-586.
[35]LI C, RAO T, CHEN X, et al. HLA-B*35∶01 allele is a potential biomarker for predicting Polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357.
[36]NICOLETTI P, AITHAL GP, BJORNSSON ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study[J]. Gastroenterology, 2017, 152(5): 1078-1089.
[37]AITHAL GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: Current role in clinical practice[J]. Liver Int, 2015, 35(7): 1801-1808.
[38]GROVE JI, AITHAL GP. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology[J]. Expert Opin Drug Metab Toxicol, 2015, 11(3): 395-409.
[39]ZHANG L, NIU M, WEI AW, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum[J]. Arch Toxicol, 2019. [Epub ahead of print]
[40]WANG JB, ZHU Y, BAI ZF, et al. Guidelines for the diagnosis and management of herb-induced liver injury[J]. Chin J Integr Med, 2018, 24(9): 696-706.